close

Products

Date: 2015-05-11

Type of information: Granting of a patent

Product name: selective inhibitors of IKK-epsilon and TBK1

Compound: selective inhibitors of IKK-epsilon and TBK1

Therapeutic area: Inflammatory diseases - Respiratory diseases

Action mechanism:

Company: Domainex (UK)

Disease:

Latest news:

 

 

Patents:

* On May 11, 2015, Domainex announced that The US and European Patent Offices have now granted Domainex patents US 8,962,609 and EPA 11738026.1 for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1. Domainex recently received an Innovate UK government grant which will enable it to progress the TBK1/IKKε programme to IND-ready status in inflammatory diseases including COPD and psoriasis. The programme is approaching candidate selection and has already shown activity in disease models of inflammation and COPD.

Submission of marketing authorization application USA :

Submission of marketing authorization application UE:

Withdrawal of marketing authorization application USA:

Withdrawal of marketing authorization application UE:

US authorization:

UE authorization:

Favourable opinion UE:

Favourable opinion USA:

Orphan status USA:

Orphan status UE:

Pediatric exclusivit _USA:

Pediatric exclusivity UE:

OTC status:

Other news:

Is general: Yes